- Masitinib appeared to delay the progression to severe Alzheimer's disease during a 24 week time frame.
- Masitinib acts as an inhibitor of tyrosine kinases which may help slow cognitive decline in mild to moderate Alzheimer's disease.
- The magnitude of this effect likely shrinks over longer time periods.
- AB Science has a checkered history in regards to conducting and reporting on its clinical trials.
- More information is needed before a sound investment decision can be made.
For further details see:
AB Science's Masitinib: An Uncertain Success For Alzheimer's Disease